Get the Stockscreener App
133.77
0.80%
-1.085
Abivax Adr stock is traded at $133.77, with a volume of 966.43K.
It is down -0.80% in the last 24 hours and up +16.49% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
See More
Previous Close:
$134.85
Open:
$136.8
24h Volume:
966.43K
Relative Volume:
0.70
Market Cap:
$10.42B
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-37.79
EPS:
-3.5401
Net Cash Flow:
$-105.22M
1W Performance:
-6.00%
1M Performance:
+16.49%
6M Performance:
+1,624%
1Y Performance:
+1,735%
1-Day Range:
$132.61
$138.69
1-Week Range:
$129.88
$147.00
52-Week Range:
$4.77
$148.83
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
133.77 | 10.51B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-06-25 | Initiated | Wolfe Research | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jul-23-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-20-25 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | Laidlaw | Buy |
| May-20-24 | Initiated | BTIG Research | Buy |
| Apr-29-24 | Initiated | Guggenheim | Buy |
| Apr-29-24 | Initiated | Piper Sandler | Overweight |
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
View All
Abivax Adr Stock (ABVX) Latest News
Is ABIVAX Societe Anonyme (ABVX) One of the Hottest Large-Cap Stocks of 2025? - Finviz
Voya Investment Management LLC Invests $978,000 in Abivax SA Sponsored ADR $ABVX - MarketBeat
61,449 Shares in Abivax SA Sponsored ADR $ABVX Purchased by Simplify Asset Management Inc. - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap UpHere's What Happened - MarketBeat
Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout - Finviz
Abivax (NASDAQ:ABVX) Trading Up 6%Time to Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Integra Lifesciences (IART) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 1-Year HighHere's Why - MarketBeat
Why Abivax Stock Was on Fire Today - Finviz
Why Abivax Stock Was on Fire Today - The Motley Fool
Why Abivax SA Sponsored ADR Shares Are Tumbling - TipRanks
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Abivax shares gain after 22 scientific abstracts accepted for ECCO 2026 - MSN
Abivax stock rises after announcing acceptance of 22 abstracts at ECCO 2026 - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Receives a Buy from Truist Financial - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Citizens Jmp Issues Positive Forecast for Abivax (NASDAQ:ABVX) Stock Price - Defense World
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers - ts2.tech
Abivax (NASDAQ:ABVX) Trading Down 5.9%Should You Sell? - MarketBeat
Abivax SA Reports Increased Losses in Q3 2025 Amid Rising R&D Costs - TipRanks
Abivax SA reports increased losses in Q3 2025 amid rising R&D costs - MSN
FY2025 EPS Estimates for Abivax Decreased by Lifesci Capital - MarketBeat
A Look at Abivax ADR (ABVX) Shares in the Recent Past Indicates Growth - setenews.com
Stempoint Capital LP Invests $671,000 in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX) - MarketBeat
Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
Abivax SA Sponsored ADR $ABVX Shares Sold by Affinity Asset Advisors LLC - MarketBeat
A3EWCP Stock Price and Chart — LSX:A3EWCP - TradingView — Track All Markets
Abivax SA Sponsored ADR $ABVX Shares Bought by Saturn V Capital Management LP - MarketBeat
Quadrature Capital Ltd Acquires Shares of 19,367 Abivax SA Sponsored ADR $ABVX - MarketBeat
Investors in cash trouble should check out Abivax ADR (ABVX) - setenews.com
Optimistic Buy Rating for Abivax SA: Potential of Obefazimod Amid Safety and Financial Considerations - TipRanks
Abivax SA Sponsored ADR Dividends – LS:A3EWCP - TradingView
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
There is no doubt that Abivax ADR (ABVX) ticks all the boxes. - Setenews
Abivax SA Sponsored ADR (ABVX) Receives a New Rating from Truist Financial - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of “Buy” from Analysts - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Abivax (NASDAQ:ABVX) Sees Large Volume IncreaseHere's Why - MarketBeat
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025 - ts2.tech
Is Abivax ADR (ABVX) positioned for future growth? - Setenews
Nothing is Better Than Kyivstar Group Ltd (KYIV) stock at the moment - Setenews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month HighStill a Buy? - MarketBeat
Abivax (NASDAQ:ABVX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know - MSN
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI) and Cellectar Biosciences (CLRB) - The Globe and Mail
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? - sharewise.com
A new trading data show Abivax ADR (ABVX) is showing positive returns. - Setenews
Akebia Therapeutics (AKBA) Receives a Buy from BTIG - The Globe and Mail
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):